A First-in-human, Two-part (Open Label, and Randomized/Double Blind/Placebo Controlled), Single- and Repeat-dose Study of CSJ137 in Erythropoietin-treated Chronic Hemodialysis Patients With Functional Iron-deficiency Anemia
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs CSJ 137 (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals Corporation
- 25 Jul 2017 Planned End Date changed from 18 Aug 2018 to 1 Jul 2019.
- 25 Jul 2017 Planned primary completion date changed from 18 Aug 2018 to 1 Jul 2019.
- 10 May 2017 Planned number of patients changed from 96 to 88.